                         SEQUENCE LISTING

<110>  Merck Sharp & Dohme Corp.
       Palaini, Ananadan
       Carrington, Paul E
       Pessi, Antonello
       Lahm, Armin
       Bianchi, Elisabetta
       Demartis, Anna
 
<120>  CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS

<130>  24224

<150>  62/264,928
<151>  2015-12-09

<160>  68    

<170>  PatentIn version 3.5

<210>  1
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  1

His Ser Val Gly Asn Phe Trp Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Leu Thr 
            20                  25                  


<210>  2
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  2

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Val Glu Asp 
1               5                   10                  15      


Arg Arg Ala His Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  3
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  3

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Arg Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Trp Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  4
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  4

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asn Ser 
1               5                   10                  15      


Trp Met Thr Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  5
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  5

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ile 
1               5                   10                  15      


Gly Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  6
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  6

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Leu Met Ala Gln Asp Phe Val Gln Trp Leu Met Ser Thr 
            20                  25                  


<210>  7
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  7

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Trp 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  8
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  8

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ile Lys Leu Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  9
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  9

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Ile Arg Thr 
            20                  25                  


<210>  10
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  10

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Val 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  11
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  11

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Leu Arg Ala Tyr Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  12
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  12

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Tyr 
1               5                   10                  15      


Met Arg Ala Tyr Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  13
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  13

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala His Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  14
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  14

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Pro 
            20                  25                  


<210>  15
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  15

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Ile Asn Tyr 
            20                  25                  


<210>  16
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  16

Ile Asn His Glu Gln Trp Ala Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 
1               5                   10                  15      


Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  30      


<210>  17
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  17

Ala Ser Met Phe Thr Phe Phe Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Leu Thr 
            20                  25                  


<210>  18
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  18

His Ser Gln Gly Thr Phe Leu Ser Asp Tyr Ser Lys Leu Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Gln Thr 
            20                  25                  


<210>  19
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  C-terminal amide

<400>  19

His Ser Gln Gly Thr Phe Leu His Asp Tyr Tyr Tyr Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr 
            20                  25                  


<210>  20
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  20

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Ile Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr 
            20                  25                  


<210>  21
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  21

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Asn 
1               5                   10                  15      


Lys Arg Ala Gln Asp Phe Val Gln Trp Leu Met Gln Thr 
            20                  25                  


<210>  22
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  22

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Asp Trp Leu Met Asn Glu 
            20                  25                  


<210>  23
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  23

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Glu Phe Val Glu Trp Leu Met Asp Glu 
            20                  25                  


<210>  24
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  24

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Ile Asn Thr 
            20                  25                  


<210>  25
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  25

Lys Ala Leu Gly Gln Phe Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 
1               5                   10                  15      


Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  30      


<210>  26
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  26

His Ser Gln Gly Thr Phe Phe His Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  27
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  27

His Ser Gln Gly Thr Phe Phe Ser Asp Tyr Ser His Trp Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  28
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  28

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Trp 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Gln Asn Thr 
            20                  25                  


<210>  29
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  29

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Lys Arg Ala His Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  30
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  30

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Trp Ile Asp Leu Met Asn Thr 
            20                  25                  


<210>  31
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  31

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Met Thr Ser Met Asn Thr 
            20                  25                  


<210>  32
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  32

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Asp Trp Leu Leu Asn Ala 
            20                  25                  


<210>  33
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  33

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Glu Trp Leu Met Asn Asn 
            20                  25                  


<210>  34
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  34

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Asp Trp Leu Ile Asn Ser 
            20                  25                  


<210>  35
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  35

His Ser His Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Thr Thr 
            20                  25                  


<210>  36
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  36

His Ser Gln Gly Ile Phe Phe Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  37
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  37

His Ser Gln Gly Thr Phe Leu Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  38
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  38

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Trp Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  39
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  39

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Met 
1               5                   10                  15      


Gln Arg Ala His Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  40
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  40

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Met Ala Tyr Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  41
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  41

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Gln 
            20                  25                  


<210>  42
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  42

His Ser Gln Gly Thr Phe Phe Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Glu Thr 
            20                  25                  


<210>  43
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  43

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Ser 
            20                  25                  


<210>  44
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  44

His Ser Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Asn 
1               5                   10                  15      


Lys Arg Ala Gln Asp Phe Val Gln Trp Leu Met Gln Thr 
            20                  25                  


<210>  45
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  45

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala His Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  46
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  46

His Xaa Gln Gly Thr Phe Leu Ser Asp Lys Ser Lys Leu Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Gln Thr 
            20                  25                  


<210>  47
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  47

His Xaa Gln Gly Thr Phe Leu Ser Asp Tyr Ser Lys Leu Leu Asp Ser 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Gln Thr 
            20                  25                  


<210>  48
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  48

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala His Asp Phe Val Gln Trp Leu Leu Asn Thr 
            20                  25                  


<210>  49
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminoisobutyric (aib)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lys is conjugated to gamma-Glu gamma-Glu C16

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amide

<400>  49

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala His Asp Phe Val Gln Trp Leu Leu Asn Thr Lys Xaa 
            20                  25                  30      


<210>  50
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminoisobutyric (aib)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lys is conjugated to gamma-Glu gamma-Glu C16

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amide

<400>  50

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala His Asp Phe Val Gln Trp Leu Leu Asn Thr Lys Xaa 
            20                  25                  30      


<210>  51
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminoisobutryic (aib)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lys is conjugated to gamma-Glu gamma-Glu C16

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amide

<400>  51

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Asn 
1               5                   10                  15      


Lys Arg Ala Gln Asp Phe Val Gln Trp Leu Met Gln Thr Lys Xaa 
            20                  25                  30      


<210>  52
<211>  29
<212>  PRT
<213>  Homo sapiens

<400>  52

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  53
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<220>
<221>  MISC_FEATURE
<222>  (29)..(30)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<400>  53

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 
1               5                   10                  15      


Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Xaa Xaa Thr 
            20                  25                  30      


<210>  54
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<220>
<221>  MISC_FEATURE
<222>  (27)..(28)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<400>  54

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Xaa Xaa Thr 
            20                  25                  


<210>  55
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(13)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<220>
<221>  MISC_FEATURE
<222>  (27)..(28)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<400>  55

His Ser Gln Gly Thr Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Xaa Xaa Thr 
            20                  25                  


<210>  56
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (14)..(20)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<220>
<221>  MISC_FEATURE
<222>  (27)..(28)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<400>  56

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Asp Phe Val Gln Trp Leu Xaa Xaa Thr 
            20                  25                  


<210>  57
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (21)..(29)
<223>  Xaa is any amino acid with the proviso that for each position in 
       45% of the peptides the amino acid is maintained as the wild type
       amino acid while in 55% of the peptides the amino acid is any 
       other amino acid except cysteine

<400>  57

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  25                  


<210>  58
<211>  32
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide

<400>  58
gactgctagc accatgcccc cctgccagcc ac                                     32


<210>  59
<211>  31
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide

<400>  59
gactgctagc accatggccg gcgcccccgg c                                      31


<210>  60
<211>  40
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide

<400>  60
atcgatcgat ttaaacctta tcgtcgtcat ccttgtaatc                             40


<210>  61
<211>  80
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide


<220>
<221>  misc_feature
<222>  (12)..(14)
<223>  wherein n12n13n14 have the triplet sequences AAA, AAT, ACT, ATA, 
       ATG,CAG, CAT, CCG, CGT, CTG, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       TGG, or TTT in which each triplet is each present 5.26% of the 
       time

<220>
<221>  misc_feature
<222>  (15)..(17)
<223>  wherein n15n16n17 have the triplet sequences

       AAA, AAT, ACT, ATA, ATG,CAG, CAT, CCG, CGT, CTG, GAA, GAT, GCT, 
       GGT, GTT, TAC, TCT, TGG, or TTT in which each triplet is each 
       present 5.26% of the time

<220>
<221>  misc_feature
<222>  (18)..(20)
<223>  wherein n18n19n20 have the triplet sequence CAT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, GAA, GAT, GCT, GGT, GTT, TAC, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (21)..(23)
<223>  wherein n21n22n23 have the triplet sequence TCT which present 45%
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CAT, CCG, CGT, CTG, GAA, GAT, GCT, GGT, GTT, TAC, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (24)..(26)
<223>  wherein n24n25n26 have the triplet sequence CAG present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG, CAT, CCG, CGT, CTG, GAA, GAT, GCT, GGT, GTT, TAC, TGG, TCT, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (27)..(29)
<223>  wherein n27n28n29 have the triplet sequence GGT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CAT, CCG, CGT, CTG, GAA, GAT, GCT, GTT, TAC, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (30)..(32)
<223>  wherein n30n31n32 have the triplet sequence ACT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ATA, 
       ATG,CAG, CAT, CCG, CGT, CTG, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       TGG, or TTT are each present 5.26% of the time

<400>  61
gccggatggc annnnnnnnn nnnnnnnnnn nntttacctc tgattacagc aaatacctgg       60

attctagacg tgctcaagac                                                   80


<210>  62
<211>  76
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide


<220>
<221>  misc_feature
<222>  (14)..(16)
<223>  wherein n14n15n16 have the triplet sequence CAT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, GAA, GAT, GCT, GGT, GTT, TAC, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (17)..(19)
<223>  wherein n17n18n19 have the triplet sequence TCT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (20)..(22)
<223>  wherein n20n21n22 have the triplet sequence CAG present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (23)..(25)
<223>  wherein n23n24n25 have the triplet sequence GGT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GTT, TAC, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (26)..(28)
<223>  wherein n26n27n28 have the triplet sequence ACT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ATA, 
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       TGG, or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (29)..(31)
<223>  wherein n29n30n31 have the triplet sequence TTT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       OR TGG are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (32)..(34)
<223>  wherein n32n33n34 have the triplet sequence ACT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ATA, 
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       TGG, or TTT are each present 5.26% of the time

<400>  62
gccggccatg gcannnnnnn nnnnnnnnnn nnnntctgat tacagcaaat acctggattc       60

tagacgtgct caagac                                                       76


<210>  63
<211>  76
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide


<220>
<221>  misc_feature
<222>  (32)..(34)
<223>  wherein n32n33n34 have the triplet sequence ACT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ATA, 
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       TGG, or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (35)..(37)
<223>  wherein n35n36n37 have the triplet sequence TCT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (38)..(40)
<223>  wherein n38n39n40 have the triplet sequence GAT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GCT, GGT, GTT, TAC, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (41)..(43)
<223>  wherein n41n42n43 have the triplet sequence TAC present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TCT, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (44)..(46)
<223>  wherein n44n45n46 have the triplet sequence TCT present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TGG, 
       or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (47)..(49)
<223>  wherein n47n48n49 have the triplet sequence AAA present 45% 
       percent of the time and the triplet sequences AAT, ACT, ATA, 
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TAC, TCT, 
       TGG, or TTT are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (50)..(52)
<223>  wherein n50n151n52 have the triplet sequence TAC present 45% 
       percent of the time and the triplet sequences AAA, AAT, ACT, ATA,
       ATG,CAG, CCG, CGT, CTG, CAT, GAA, GAT, GCT, GGT, GTT, TCT, TGG, 
       or TTT are each present 5.26% of the time

<400>  63
gccggccatg gcacattctc agggtacctt tnnnnnnnnn nnnnnnnnnn nnctggattc       60

tagacgtgct caagac                                                       76


<210>  64
<211>  52
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide

<400>  64
gccggccatg gcacattctc agggtacctt caccagcgac tacagcaagt ac               52


<210>  65
<211>  67
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide

<400>  65
ccggccatgg cacattctca gggtaccttt acctctgatt atagcaagta tctggattct       60

cgtcgtg                                                                 67


<210>  66
<211>  61
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide


<220>
<221>  misc_feature
<222>  (19)..(21)
<223>  wherein n19n20n21 have the triplet sequence GTT present 45% of 
       the time and the triplet sequences TTT, CGT, AAT, CAT, CTG, ATG, 
       CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, or AAA are
       each present 5.36% of the time

<220>
<221>  misc_feature
<222>  (22)..(24)
<223>  wherein n19n20n21 have the triplet sequence CAT present 45% of 
       the time and the triplet sequences TTT, GTT, CGT, AAT, CTG, ATG, 
       CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, or AAA are
       each present 5.36% of the time

<400>  66
ctgtgcggcc gcaccagtnn nnnncagcca ctgaacaaag tcttgagcac gtctagaatc       60

c                                                                       61


<210>  67
<211>  85
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide


<220>
<221>  misc_feature
<222>  (19)..(21)
<223>  wherein n19n20n21 have the triplet sequence GTT present 45% 
       percent of the time and the triplet sequences TTT, CGT, AAT, CAT,
       CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (22)..(24)
<223>  wherein n22n23n24 have the triplet sequence CAT present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (43)..(45)
<223>  wherein n43n44n45 have the triplet sequence CTG present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (46)..(48)
<223>  wherein n46n47n48 have the triplet sequence TGC present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, ATC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (49)..(51)
<223>  wherein n49n50n51 have the triplet sequence TCT present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (52)..(54)
<223>  wherein n52n53n54 have the triplet sequence ACT present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (55)..(57)
<223>  wherein n55n156n57 have the triplet sequence ATC present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, 
       CCA, or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (58)..(60)
<223>  wherein n58n59n60 have the triplet sequence CAG present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (61)..(63)
<223>  n is a, c, g, or t

<400>  67
ctgtgcggcc gcaccagtnn nnnncagcca ctgaacgaag tcnnnnnnnn nnnnnnnnnn       60

nnngtacttg ctgtagtcgc tggtg                                             85


<210>  68
<211>  70
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oligonucleotide


<220>
<221>  misc_feature
<222>  (16)..(18)
<223>  wherein n16n17n18 have the triplet sequence CGT present 45% 
       percent of the time and the triplet sequences TTT, GTT, AAT, CAT,
       CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (19)..(21)
<223>  wherein n19n20n21 have the triplet sequence GTT present 45% 
       percent of the time and the triplet sequences TTT, CGT, AAT, CAT,
       CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (22)..(24)
<223>  wherein n22n23n24 have the triplet sequence CAT present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (25)..(27)
<223>  wherein n25n26n27 have the triplet sequence CAG present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (28)..(30)
<223>  wherein n28n29n30 have the triplet sequence CCA present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (31)..(33)
<223>  wherein n31n32n33 have the triplet sequence CTG present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (34)..(36)
<223>  wherein n34n35n36 have the triplet sequence AAC present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (37)..(39)
<223>  wherein n37n38n39 have the triplet sequence AAA present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, ATC, TGC, ACC, AAC, ATA, ACT, 
       or CCA are each present 5.26% of the time

<220>
<221>  misc_feature
<222>  (40)..(42)
<223>  wherein n40n41n42 have the triplet sequence ATC present 45% 
       percent of the time and the triplet sequences TTT, GTT, CGT, AAT,
       CAT, CTG, ATG, CGG, TCT, CAG, TTC, TGC, ACC, AAC, ATA, ACT, CCA, 
       or AAA are each present 5.26% of the time

<400>  68
ctgtgcggcc gcactnnnnn nnnnnnnnnn nnnnnnnnnn nnctgagcac gacgagagtc       60

cagatacttg                                                              70


